The Discounted Cash Flow (DCF) valuation of Recursion Pharmaceuticals Inc (RXRX) is (132.41) USD. With the latest stock price at 5.03 USD, the upside of Recursion Pharmaceuticals Inc based on DCF is -2732.5%.
Based on the latest price of 5.03 USD and our DCF valuation, Recursion Pharmaceuticals Inc (RXRX) is a sell. selling RXRX stocks now will result in a potential gain of 2732.5%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.4% - 9.2% | 7.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (347.96) - (82.19) | (132.41) |
| Upside | -7017.7% - -1733.9% | -2732.5% |